Abbott (NYSE:ABT) was honored for a handful of its offerings at the Consumer Electronics Show (CES) 2022 Innovation Awards.
The company’s FreeStyle Libre 3 continuous glucose monitoring (CGM) system ranked among the top 15 products in the CES “Best of Innovation” category. The next-generation CGM system features the world’s smallest, thinnest glucose sensor that can be worn up to 14 days to deliver continuous, real-time glucose readings directly to smartphones with strong accuracy and performance.
Abbott said in a news release that, in an effort to keep it affordable and accessible to those in need, FreeStyle Libre 3 has remained at the same price as previous generations of the platform.
CES honored the highest-rated products across more than two-dozen categories for its “Best of Innovation” honor, with Judges rating products on aspects including engineering and functionality, aesthetic and design and what makes them unique and/or innovative.
Other Abbott products to receive honors included the Libre Sense Glucose Sport Biosensor, the first device intended to help athletes track blood sugar rather than people with diabetes, the company’s BinaxNOW COVID-19 self tests and accompanying Navica digital app and the i-Stat TBI plasma test.
The company also received recognition for its Ultreon 1.0 software, which powers Abbott’s optical coherence tomography (OCT) platform, using near-infrared light to reflect off the structures of vessels, providing cardiologists a way to procure precise measurements and obtain a lot of information about the composition of vessel narrowings.
Among other honorees in the “Health & Wellness” category were ResMed and Grapheal.
ResMed received recognition for its AirSense 11 cloud-connected positive airway pressure (PAP) device for treating sleep apnea. The platform includes AirView remote patient monitoring and the myAir patient engagement platform.
Grapheal’s TestNpass standalone digital “test strip” connects to a smartphone and, after testing, turns into a personal and secure radio-frequency identification (RFID) pass. The platform screens for the presence of biomarkers in body fluids, with the first model targeting antigens caused by COVID-19 infection. It provides a secure, biometric health pass in less than five minutes.